scholarly journals Penfigoide Bolhoso Tratado com Sucesso com Rituximab

2017 ◽  
Vol 30 (3) ◽  
pp. 243 ◽  
Author(s):  
Nuno Silva ◽  
Andreia Costa ◽  
Fernando Salvador ◽  
Elisa Serradeiro
Keyword(s):  
Autoimmune Disease ◽  
Bullous Pemphigoid ◽  
Biological Agents ◽  
First Line ◽  
Blister Formation ◽  
Subepidermal Blister

Bullous pemphigoid is an autoimmune disease characterized by subepidermal blister formation. Can be self-limiting but when necessary treatment includes the use of corticosteroids, immunosuppressants, and biological agents. We present the case of a 37 year old patient with a severe and refractory presentation of bullous pemphigoid. After about a month of treatment with various first line drugs and with no response, we chose to start rituximab and clear improvement of the lesions was observed. The authors aim to highlight the usefulness and effectiveness of this drug in this disease.

Monocytes enhance neutrophil-induced blister formation in an ex vivo model of bullous pemphigoid

Allergy ◽  
2018 ◽  
Vol 73 (5) ◽  
pp. 1119-1130 ◽  
Author(s):  
E. de Graauw ◽  
C. Sitaru ◽  
M. P. Horn ◽  
L. Borradori ◽  
S. Yousefi ◽  
...  
Keyword(s):  
Bullous Pemphigoid ◽  
Ex Vivo ◽  
Ex Vivo Model ◽  
Blister Formation

scholarly journals Alemtuzumab Induced Thyroid Disease in Multiple Sclerosis: A Review and Approach to Management

2015 ◽  
Vol 42 (5) ◽  
pp. 284-291 ◽  
Author(s):  
Moeber Mahzari ◽  
Amel Arnaout ◽  
Mark S. Freedman
Keyword(s):  
Multiple Sclerosis ◽  
Monoclonal Antibody ◽  
Autoimmune Disease ◽  
Thyroid Gland ◽  
Thyroid Disease ◽  
Thyroid Dysfunction ◽  
Simple Approach ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment

AbstractAlemtuzumab, an anti-CD52 monoclonal antibody, was recently approved for treatment of MS in Canada, having shown to significantly reduce relapses and disability in patients, particularly those who relapsed despite first line treatment. Offsetting its benefit however, is the development of novel secondary autoimmune disease, particularly affecting the thyroid gland in up to 36% of patients. The incidence of Alemtuzumab induced thyroid dysfunction (AITD) will likely rise as alemtuzumab becomes more widely used for treating MS. We review the clinical and investigational cues that help delineate the aetiology and management of thyrotoxicosis and hypothyroidism in ATID. AITD can be easily managed and we present a simple approach for its evaluation and management by neurologists that should be implemented prior to considering a referral to an internist or endocrinologist for further opinion or treatment.

FRI0127 Treatment Targets with First Line Biological Agents in Early and Longstanding Rheumatoid Arthritis Patients

2015 ◽  
Vol 74 (Suppl 2) ◽  
pp. 467.1-467
Author(s):  
P. Conigliaro ◽  
P. Triggianese ◽  
F. Sunzini ◽  
I. Duca ◽  
M. Barba ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Biological Agents ◽  
First Line ◽  
Treatment Targets

scholarly journals Bullous Pemphigoid Associated with Adalimumab Therapy in a Patient with Ulcerative Colitis

2018 ◽  
Vol 10 (2) ◽  
pp. 145-148 ◽  
Author(s):  
Sebastian Hoffmann ◽  
Mark Berneburg ◽  
Stephan Schreml
Keyword(s):  
Ulcerative Colitis ◽  
Autoimmune Disease ◽  
Elderly Patients ◽  
Bullous Pemphigoid ◽  
Lupus Erythematosus ◽  
Systemic Therapy ◽  
Rare Case ◽  
Case Reports ◽  
Adalimumab Therapy ◽  
Tnf Inhibition

Bullous pemphigoid (BP) is a blistering autoimmune disease mainly observed in elderly patients. Several triggers are known for this autoimmune disease and some drugs are known to be a cause of BP. However, there are only few case reports on the induction of BP under adalimumab therapy. Other autoimmune diseases, such as lupus erythematosus, are also known to occur under TNF inhibition. Here, we report on an 81-year-old patient who received adalimumab for ulcerative colitis and subsequently developed BP. Other causes of BP (tumors, other drugs, viral or toxoplasma infections) were excluded. We initiated a topical and systemic therapy (prednisolone 1 mg/kg/day) and stopped the adalimumab injections. The patient’s symptoms resolved quickly and we were able to taper corticosteroid therapy. This rare case highlights the importance to monitor for autoimmune events during TNF inhibition.

scholarly journals Bullous Pemphigoid Autoantibodies Directly Induce Blister Formation without Complement Activation

2014 ◽  
Vol 193 (9) ◽  
pp. 4415-4428 ◽  
Author(s):  
Hideyuki Ujiie ◽  
Tetsumasa Sasaoka ◽  
Kentaro Izumi ◽  
Wataru Nishie ◽  
Satoru Shinkuma ◽  
...  
Keyword(s):  
Bullous Pemphigoid ◽  
Complement Activation ◽  
Blister Formation

scholarly journals Identification of a Potential Effector Function for IgE Autoantibodies in the Organ-Specific Autoimmune Disease Bullous Pemphigoid

2003 ◽  
Vol 120 (5) ◽  
pp. 784-788 ◽  
Author(s):  
Otobia G. Dimson ◽  
George J. Giudice ◽  
Chang Ling Fu ◽  
Francoise Van den Bergh ◽  
Simon J. Warren ◽  
...  
Keyword(s):  
Autoimmune Disease ◽  
Bullous Pemphigoid ◽  
Effector Function ◽  
Organ Specific

Cell mediated immune reaction in the mechanism of blister formation in bullous pemphigoid

1990 ◽  
Vol 1 (2) ◽  
pp. 120
Author(s):  
Y. Takiguchi ◽  
O. Kamiyama ◽  
E. Saito ◽  
M. Suzuki ◽  
F. Kaneko
Keyword(s):  
Bullous Pemphigoid ◽  
Immune Reaction ◽  
Blister Formation

scholarly journals Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid

2021 ◽  
Vol 12 ◽  
Author(s):  
Yihua Zhang ◽  
Qiuyun Xu ◽  
Lihong Chen ◽  
Jiawen Chen ◽  
Jing Zhang ◽  
...  
Keyword(s):  
Median Time ◽  
Bullous Pemphigoid ◽  
The Elderly ◽  
Conventional Group ◽  
Treatment Modalities ◽  
Biologic Agent ◽  
Blister Formation ◽  
Minimal Dose ◽  
Kaplan Meier ◽  
Systemic Glucocorticoids

BackgroundBullous pemphigoid (BP) is an autoimmune blistering disorder that predominantly affects the elderly. As the main treatment for BP, systemic corticosteroids are often limited by their side effects. Safer treatment modalities are therefore needed. Dupilumab is a biologic agent used to treat BP in recent years.MethodsMedical records of patients with moderate-to-severe BP were retrospectively reviewed. Twenty-four patients were included (follow-up period: 32 weeks), eight of whom received dupilumab in combination with methylprednisolone and azathioprine (dupilumab group) while the other 16 patients received methylprednisolone and azathioprine (conventional group). Response to dupilumab was evaluated by comparison of several parameters (time to stop new blister formation, time to reduce the systemic glucocorticoids to minimal dose, and total amount of methylprednisolone).ResultsThe median age of patients in the dupilumab and conventional groups were 64.50 years (range: 22–90 years) and 64.50 years (range: 17–86 years), respectively. The median duration of disease before admission in the dupilumab group was 2 months (range: 1–240 months) and 2.5 months (range: 1–60 months) in the conventional group. The median time to stop new blister formation was 8 days (range: 1–13 days) and 12 days (range: 5–21 days) in patients of the dupilumab and conventional groups, respectively (p = 0.028 by Kaplan-Meier analysis). In addition, the median time to reduce the systemic glucocorticoids to minimal dose (methylprednisolone 0.08 mg/kg/day) was 121.5 and 148.5 days for the dupilumab and conventional therapy groups, respectively (p = 0.0053 by Kaplan-Meier analysis). The median total amount of methylprednisolone (at the time of reaching the minimal dose) used in the dupilumab group was 1,898 mg (range: 1,624–2,932 mg) while the cumulative dose of conventional group was 2,344 mg (range: 1,708–4,744 mg) (p = 0.036 by Mann-Whitney U test). The median total amount of azathioprine (at the time of reaching the minimal dose) used in dupilumab group was 8,300 mg (range: 7,100–10,400 mg) while the total dose of conventional group was 10,300 mg (range: 8,900–14,400 mg) (p = 0.0048 by Mann-Whitney U test). No adverse event related to dupilumab was recorded.ConclusionsDupilumab in addition to methylprednisolone and azathioprine seems superior to methylprednisolone/azathioprine alone in controlling disease progression and accelerating the tapering of glucocorticoids.

Sign in / Sign up

Export Citation Format

Share Document